secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001753926-22-001463
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports Q3 net income $1.4M on merger gain; NPM-119 on track for IND early 2023
--------------------------------------------------------------------------------

- Net income of $1.4M in Q3 2022 vs net loss of $3.5M in Q3 2021, driven by $6.9M bargain purchase gain from merger.
- Cash and equivalents $51.7M as of Sep 30, 2022; estimated to fund operations into second half of 2024.
- R&D expenses $3.9M (up 34% YoY); G&A $1.6M (up 167% YoY) due to higher headcount from merger.
- NPM-119 GLP-1 implant IND filing and LIBERATE-1 Phase 2 start expected early 2023; top-line results anticipated late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/0001753926-22-001463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/g083264_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-22-001463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer